Sensei Biotherapeutics, Inc.
SNSEHeld by 4 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying4 funds opened new positions. Next phase2 readout (SNS-101 (anti-VISTA)): Jun 2027. Short interest: 84.6% of float.
Held by 4 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying4 funds opened new positions. Next phase2 readout (SNS-101 (anti-VISTA)): Jun 2027. Short interest: 84.6% of float.
Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform. This immunotherapy leverages bacteriophages to orchestrate a precise and robust innate and adaptive immune response. They also employ the Tumor Microenvironment Activated Biologics (TMAB) platform. This system is engineered to unleash T-cells' anti-tumor capabilities, utilizing human monoclonal antibodies specifically designed to operate within the tumor's immediate environment and target key immune checkpoints or other crucial signaling pathways. Sensei Biotherapeutics' pipeline features SNS-101, a monoclonal antibody developed for cancer therapy, and SNS-401-NG, an ImmunoPhage vaccine engineered to target a range of tumor antigens. Furthermore, they collaborate with The University of Washington on the research and development of a vaccine for Merkel cell carcinoma. Established in 1999, originally as Panacea Pharmaceuticals, Inc., Sensei Biotherapeutics maintains its headquarters in Rockville, Maryland.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.